In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia

Angelo M. Carella, Anna Dejana, Enrica Lerma, Marina Podesta, Federica Benvenuto, Francesca Chimirri, Caterina Parodi, Mario Sessarego, Emma Prencipe, Francesco Frassoni

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

We have previously reported that mobilization of Philadelphia (Ph) chromosome-negative progenitors is possible in a significant number of Ph1-positive acute lymphoblastic leukaemia (ALL) and chronic myelogenous leukaemia (CML) patients. In this pilot study we employed the same approach for patients with RAEB-t, secondary AML (sAML) and therapy-related AML (t-AML). All patients except one had double or complex cytogenetic abnormalities in marrow cells before mobilization therapy. All patients received an idarubicin-containing regimen (mini-ICE protocol) followed by rh-G-CSF and the first leukapheresis was performed as they were recovering from aplasia. In six out of nine patients the leukapheresis product was entirely karyotypically normal, combined with a significant number of CFU-GM, CD34+ cells and LTC-IC. Recovery time from mobilization therapy was short and no patient died as a result of the procedure. To date, three patients have undergone autografting using their karyotypically normal collections, of which two (sAML) are alive with karyotypically normal marrow a few months after autografting.

Original languageEnglish
Pages (from-to)127-130
Number of pages4
JournalBritish Journal of Haematology
Volume95
Issue number1
Publication statusPublished - 1996

Fingerprint

Acute Myeloid Leukemia
Blood Cells
Stem Cells
Leukapheresis
Autologous Transplantation
Therapeutics
Bone Marrow
Idarubicin
Refractory Anemia with Excess of Blasts
Philadelphia Chromosome
Granulocyte-Macrophage Progenitor Cells
Granulocyte Colony-Stimulating Factor
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Chromosome Aberrations

Keywords

  • 'normal' PBPC mobilization
  • high-risk sAML

ASJC Scopus subject areas

  • Hematology

Cite this

In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. / Carella, Angelo M.; Dejana, Anna; Lerma, Enrica; Podesta, Marina; Benvenuto, Federica; Chimirri, Francesca; Parodi, Caterina; Sessarego, Mario; Prencipe, Emma; Frassoni, Francesco.

In: British Journal of Haematology, Vol. 95, No. 1, 1996, p. 127-130.

Research output: Contribution to journalArticle

Carella, Angelo M. ; Dejana, Anna ; Lerma, Enrica ; Podesta, Marina ; Benvenuto, Federica ; Chimirri, Francesca ; Parodi, Caterina ; Sessarego, Mario ; Prencipe, Emma ; Frassoni, Francesco. / In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. In: British Journal of Haematology. 1996 ; Vol. 95, No. 1. pp. 127-130.
@article{132ea5d95bec4b959aaeed864cf76bed,
title = "In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia",
abstract = "We have previously reported that mobilization of Philadelphia (Ph) chromosome-negative progenitors is possible in a significant number of Ph1-positive acute lymphoblastic leukaemia (ALL) and chronic myelogenous leukaemia (CML) patients. In this pilot study we employed the same approach for patients with RAEB-t, secondary AML (sAML) and therapy-related AML (t-AML). All patients except one had double or complex cytogenetic abnormalities in marrow cells before mobilization therapy. All patients received an idarubicin-containing regimen (mini-ICE protocol) followed by rh-G-CSF and the first leukapheresis was performed as they were recovering from aplasia. In six out of nine patients the leukapheresis product was entirely karyotypically normal, combined with a significant number of CFU-GM, CD34+ cells and LTC-IC. Recovery time from mobilization therapy was short and no patient died as a result of the procedure. To date, three patients have undergone autografting using their karyotypically normal collections, of which two (sAML) are alive with karyotypically normal marrow a few months after autografting.",
keywords = "'normal' PBPC mobilization, high-risk sAML",
author = "Carella, {Angelo M.} and Anna Dejana and Enrica Lerma and Marina Podesta and Federica Benvenuto and Francesca Chimirri and Caterina Parodi and Mario Sessarego and Emma Prencipe and Francesco Frassoni",
year = "1996",
language = "English",
volume = "95",
pages = "127--130",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "1",

}

TY - JOUR

T1 - In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia

AU - Carella, Angelo M.

AU - Dejana, Anna

AU - Lerma, Enrica

AU - Podesta, Marina

AU - Benvenuto, Federica

AU - Chimirri, Francesca

AU - Parodi, Caterina

AU - Sessarego, Mario

AU - Prencipe, Emma

AU - Frassoni, Francesco

PY - 1996

Y1 - 1996

N2 - We have previously reported that mobilization of Philadelphia (Ph) chromosome-negative progenitors is possible in a significant number of Ph1-positive acute lymphoblastic leukaemia (ALL) and chronic myelogenous leukaemia (CML) patients. In this pilot study we employed the same approach for patients with RAEB-t, secondary AML (sAML) and therapy-related AML (t-AML). All patients except one had double or complex cytogenetic abnormalities in marrow cells before mobilization therapy. All patients received an idarubicin-containing regimen (mini-ICE protocol) followed by rh-G-CSF and the first leukapheresis was performed as they were recovering from aplasia. In six out of nine patients the leukapheresis product was entirely karyotypically normal, combined with a significant number of CFU-GM, CD34+ cells and LTC-IC. Recovery time from mobilization therapy was short and no patient died as a result of the procedure. To date, three patients have undergone autografting using their karyotypically normal collections, of which two (sAML) are alive with karyotypically normal marrow a few months after autografting.

AB - We have previously reported that mobilization of Philadelphia (Ph) chromosome-negative progenitors is possible in a significant number of Ph1-positive acute lymphoblastic leukaemia (ALL) and chronic myelogenous leukaemia (CML) patients. In this pilot study we employed the same approach for patients with RAEB-t, secondary AML (sAML) and therapy-related AML (t-AML). All patients except one had double or complex cytogenetic abnormalities in marrow cells before mobilization therapy. All patients received an idarubicin-containing regimen (mini-ICE protocol) followed by rh-G-CSF and the first leukapheresis was performed as they were recovering from aplasia. In six out of nine patients the leukapheresis product was entirely karyotypically normal, combined with a significant number of CFU-GM, CD34+ cells and LTC-IC. Recovery time from mobilization therapy was short and no patient died as a result of the procedure. To date, three patients have undergone autografting using their karyotypically normal collections, of which two (sAML) are alive with karyotypically normal marrow a few months after autografting.

KW - 'normal' PBPC mobilization

KW - high-risk sAML

UR - http://www.scopus.com/inward/record.url?scp=10244260460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10244260460&partnerID=8YFLogxK

M3 - Article

VL - 95

SP - 127

EP - 130

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -